Form 4: LAVA Therapeutics NV: CEO Stephen A. Hurly Granted Stock Options

CEO Stephen A. Hurly of LAVA Therapeutics NV was granted options to purchase 335,100 common shares on February 13, 2025, vesting monthly over four years.

Summary

• Stephen A. Hurly, CEO of LAVA Therapeutics NV, was granted options to purchase 335,100 common shares.
• The transaction occurred on February 13, 2025.
• The exercise price of the options is $0.93 per share.
• The options vest in 48 equal monthly installments starting March 13, 2025, contingent upon continued service with the company.
• The options expire on March 12, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders. The vesting schedule promotes long-term commitment.

Positives

• The granting of stock options to the CEO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives. The size and terms of the grant are typical for a company of LAVA Therapeutics' size and stage.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Comparable companies like Harpoon Therapeutics or BioNTech also utilize stock options to incentivize their leadership teams.
• The vesting schedule of 48 months is a common practice to ensure long-term commitment.

Stakeholder Impact

• Shareholders may view the option grant as a positive incentive for the CEO.
• Employees may see this as a sign of confidence in the company's future.

Key Dates

Keywords

LAVA Therapeutics, Stock Options, CEO, Stephen A. Hurly, Equity, Compensation, LVTX